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Abstract
About one third of cancers harbor activating mutations in rat sarcoma viral oncogene homolog 
(RAS) oncogenes. In melanoma, aberrant neuroblastoma-RAS (NRAS) signaling fuels tumor 
progression in about 20% of patients. Current therapeutics for NRAS driven malignancies barely 
impact overall survival. To date, pathway interference downstream of mutant NRAS seems to be 
the most promising approach. In this study, data revealed that mutant NRAS induced Plk1 
expression, and pharmacologic inhibition of Plk1 stabilized the size of NRAS mutant melanoma 
xenografts. The combination of MEK and Plk1 inhibitors resulted in a significant growth 
reduction of NRAS mutant melanoma cells in vitro, and regression of xenografted NRAS mutant 
melanoma in vivo. Independent cell cycle arrest and increased induction of apoptosis underlies the 
synergistic effect of this combination. Data further suggest that the p53 signaling pathway is of 
key importance to the observed therapeutic efficacy. This study provides in vitro, in vivo and first 
mechanistic data, that a MEK/Plk1 inhibitor combination might be a promising treatment 
approach for patients with NRAS driven melanoma. Since mutant NRAS signaling is similar 
across different malignancies, this inhibitor combination could also offer a previously unreported 
treatment modality for NRAS mutant tumors of other cell origins.
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Introduction
Mutations in the Neuroblastoma Rat Sarcoma viral oncogene homolog (NRAS) gene 
account for up to 20% of driving oncogenes in melanoma, making NRAS an enticing target 
for treatment (Jakob et al. 2012; Fedorenko et al. 2013). Although small molecule inhibitors 
directed against the constitutively active protein would be ideal, selectively targeting mutant 
RAS in vivo has thus far proven to be impossible (Eskandarpour et al. 2005; Jaiswal et al. 
2009; Kelleher and McArthur 2012). Current therapeutics barely impact overall survival, 
emphasizing the need for improved treatment modalities.
Recent advances in the treatment of NRAS mutant melanoma arise from interfering with key 
downstream signaling cascades of RAS, such as the mitogen activated protein kinase 
(MAPK), PI3K and Ral pathways as well as cell cycle regulator proteins. The MAPK 
pathway is critical for anchorage independent growth and survival of melanoma cells 
(Mishra et al. 2010; Atefi et al. 2011; Greger et al. 2012; Posch et al. 2013; Rebecca et al. 
2014). Still, single inhibitor treatment, targeting this pathway only marginally improved 
overall survival (Ascierto et al. 2013). MAPK reactivation and increased signaling through 
other pro-survival cascades such as the PI3K/mammalian target of rapamycin (mTOR) 
and/or cell cycle pathways cause resistance to treatment after only months of therapy 
(Catalanotti et al. 2013; Long et al. 2014). Accordingly, current research focuses on the 
development of effective inhibitor combinations (Kwong et al. 2012; Posch et al. 2013).
In this study, we show that the expression of the mitotic regulator, Polo-like kinase 1 (Plk1) 
is increased in a large panel of NRAS mutant melanoma cells. It has been established 
previously, that Plk1 directly contributes to malignant transformation and is over expressed 
in various cancers, including melanoma (Wolf et al. 1997; Knecht et al. 1999; Gray et al. 
2004; Jalili et al. 2011). Still, Plk1 inhibition alone did not meet preclinical expectations in 
recent clinical trials (Lin et al. 2014; Stadler et al. 2014).
The induction of Plk1 by mutant NRAS and the importance of the MAPK pathway for 
tumor cell homeostasis, provided the rationale to investigate the combination of a MEK and 
a Plk1 inhibitor for the treatment of NRAS mutant melanoma. This study provides first 
evidence that combined MEK and Plk1 inhibitor treatment induces apoptosis and 
synergistically inhibits NRAS mutant melanoma in vitro and in vivo.
Results
Plk1 is over-expressed in melanoma cells bearing NRAS(Q61) mutations
To study Plk1 mRNA expression in melanoma, we performed real time qPCR in 23 human 
melanoma cell lines bearing the most common melanoma driving mutations. Cell lines are 
known to harbor mutations in v-Raf murine sarcoma viral oncogene homolog B (BRAF), 
NRAS, C-KIT and guanine nucleotide-binding protein G(q) subunit alpha/11 (GNAQ/
GNA11). One cell line was wild type for the above mentioned mutations. We found Plk1 
expression in all 23 cell lines. On average, NRAS mutant cell lines expressed high levels of 
Plk1 mRNA, particularly compared to BRAF mutant melanoma cells (Fig. 1a). C-KIT, 
GNAQ and GNA11 mutant melanoma cell lines also displayed increased Plk1 levels 
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compared to BRAF lines tested (table S1). To investigate a potential correlation between 
NRAS mutations and Plk1 expression levels, we stably transduced primary human 
melanocytes (PMH) with different NRAS vectors. PHM bearing a NRAS(Q61) mutation 
showed significantly increased Plk1 mRNA and protein levels compared to PHM transduced 
with NRAS(G12), non-mutagenic NRAS(N24), or empty vector controls (E) (Fig. 1b).
Small molecule inhibitors of Plk1 and MEK reduce growth of NRAS mutant melanoma cell 
lines in vitro
In this study we used JTP-74057 (trametinib) for selective MEK inhibition and BI6727 
(volasertib) for selective Plk1 inhibition. BI6727 has previously been shown to be a highly 
potent and selective inhibitor of Plk1 (IC50=0.87nM), while failing to show any inhibitory 
activity in a panel of >50 kinases up to a drug concentration of 10NM (Rudolph et al, 2009). 
Both inhibitors have previously been demonstrated to be more potent than several other 
small molecule compounds currently available for selective inhibition of the desired targets 
(Schmit et al. 2009; Posch et al. 2013). Inhibitor concentrations to reach 50% growth 
inhibition (GI50) varied across cell lines (Fig. 2, S1), with several cells displaying GI50 in 
the low nanomolar range. All NRAS mutant cells, except WM1366, required higher 
concentrations of the Plk1 inhibitor compared to the MEK inhibitor for equipotent growth 
inhibition (Fig. 2, S1, table S2). WM3629 cells had a mutation in the Plk1 gene at 633(C>T) 
(table S1); However, WM3629 cells showed a decrease in cell viability after Plk1 inhibition 
comparable to Plk1 wild type cells.
Signaling changes following inhibitor treatment were examined by a custom mRNA array 
and immunoblotting (Fig. 3). Plk1 inhibition affected several genes involved in the cell 
cycle regulation, with a reduction of E2F1, CDC25A, CCNE1 and RB1 expression observed 
after 24h of incubation. The MEK inhibitor (MEKi) reduced several cell cycle related genes 
and induced mRNA levels of CEBPD, which has been reported to be involved in cell cycle 
regulation and programmed cell death (Balamurugan and Sterneck 2013). We observed an 
increase of MAPK1 and MAPK3 mRNA levels by the MEKi (Fig. 3a) and elevated mRNA 
levels of BCL2L1, an inhibitor of cell death. Immunoblot analyses showed comparable 
regulation in select targets at the protein level (Fig. S2). Additionally, we found reduced p-
S6 and extinguished p-ERK protein levels after MEKi treatment. p-AKT was induced in Sk-
Mel-2 cells after MEKi treatment, as previously described (Posch et al. 2013). Plk1 
inhibition resulted in a modest to pronounced increase of CCNB1 protein levels in Sk-Mel-2 
and D04 cells, respectively (Fig. 3a and 3b).
Pharmacologic targeting of MEK and Plk1 synergistically inhibits NRAS mutant melanoma 
cells
Whereas the effects of single inhibitor treatment on cell viability varied across cell lines, the 
combination of a MEK and Plk1 inhibitor (Plk1i) potently reduced growth in all 10 human 
NRAS melanoma cells tested (Fig. 2 and S1). Several different ratios of the two components 
were assayed for synergism. Calculating the combination index (CI), which indicates 
whether a certain combination is synergistic, additive, or antagonistic (table S3), revealed 
synergistic growth inhibition with several different ratios in select cell lines; however, all 
NRAS mutant lines were synergistically inhibited with a ratio of MEK:Plk1=1:8 (Fig. S3). 
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Non-transformed melanocytes as well as a BRAF mutant cell line showed no further 
decrease in cell viability by the addition of the Plk1i to the MEKi (Fig. S4). Table S2 
summarizes GI50, CI values and the dose reduction index (DRI), which indicates how much 
the dose of each drug in a synergistic combination may be reduced at a given effect level, 
compared with the doses of each drug alone (Chou and Talalay 1984).
Signaling changes due to combination inhibitor treatment were assessed by a custom mRNA 
array. Cell cycle related genes CCND1, CDC25A, CHEK2, E2F1, AurkB, and Plk1 were 
potently reduced after 24h of incubation with the MEK/Plk1 combination. Following 24h 
incubation with the MEK/Plk1 combination, induction of MAPK3 was less pronounced 
compared to MEKi treatment alone. Interestingly, when comparing the two time points (6h, 
24h), we observed induction of MDM2 and CDKN1A at 24h in both the MEK and Plk1 
treatment groups, which persisted in the combinational group, suggesting regulation of 
p53/p21 signaling. Additionally, Plk1 inhibition attenuated mRNA levels of the pro-survival 
gene BCL2L1 in the combinational therapy when compared to the observed induction of 
BCL2L1 after single MEKi treatment. Furthermore, we observed an earlier and stronger 
induction of pro-apoptotic signals, such as caspase3/7 with the MEK/Plk1 combination (Fig. 
3a, 3b, 4a, 4b, S5).
Inhibition of MEK and Plk1 results in independent, dual cell cycle arrests in a phase 
dependent manner
Since several cell cycle related genes were affected by the MEK/Plk1 combination, we 
investigated cell cycle profiles by flow cytometry. Sk-Mel-2 cells were incubated with 
varying doses of a MEKi, a Plk1i, or DMSO control in both mono and combination 
therapies (Fig. 4c). In support of our results showing decreased transcription of cyclin D, we 
observed a cell cycle arrest at G0/G1 in both MEKi treated groups. In contrast, the Plk1i 
treated groups showed a G2/M arrest. Interestingly, when cells are treated with the MEK/
Plk1 combination, they arrest in both G1 and G2/M phases in a dose dependent manner (Fig. 
4c). Protein levels of cyclins D, E, and B in Sk-Mel-2 cells were similar to the transcript 
data, showing reduced, slightly decreased and increased expression, respectively (Fig. S2). 
Taken together, these data suggest that the drugs are capable of inducing cell cycle arrest at 
distinct phases, with a potential overlap during DNA replication.
To determine if the induced cell cycle arrest is dependent on the current phase progression 
of the cell, we synchronized Sk-Mel-2 cells in late G1 using a thymidine block. Analyses 
revealed that cells treated with MEKi had an observable release from G1 at eight hours, but 
to a lesser extent than that of the control condition (Fig. 4d). Additionally, MEKi treated 
cells maintained a larger G1 population compared to the other treatment groups throughout 
the duration of the experiment, suggesting MEK inhibition is capable of inducing an arrest 
beyond the restriction point (Fig. S6). Further evidence of G1 arrest was seen by comparing 
the combination with the Plk1i treatment groups in the 18-24 hour ranges. Importantly, the 
progressing population in the combinational treatment group succumbs to G2/M arrest 
induced by the Plk1i.
A second synchronization at G2/M was achieved by using a thymidine-nocodazole block 
(Fig. 4e). Following release, the control cells progressed through mitosis and returned to a 
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G0/G1 state at two to four hours post synchronization, with a second cell division cycle 
occurring in the 18-24 hour range. However, the Plk1i treated cells failed to release from 
mitosis and maintained a G2/M arrest. Comparing the combinational group to Plk1i alone at 
24 hours after release from G2/M synchronization, there was a measurable, but not 
significant increase in the G1 population in MEK/Plk1 treated cells (Fig. S6). Altogether, 
these findings point into the direction that cells escaping Plk1i mediated arrest maintain 
sensitivity to MEK inhibition.
Reduction of cell viability by the MEK/Plk1 combination is most effective in cells 
expressing p53
In our study, results of the custom mRNA array revealed regulation of genes in the p21/p53 
pathway when cells were treated with the MEK/Plk1 combination. After 24 hours, mRNA 
levels of the p53 transcriptional targets MDM2 and CDKN1A were increased in both Sk-
Mel-2 and D04 lines (Fig. 3a). Conversely, MM485 cells with no detectable levels of 
phospho-p53 had decreased levels of both transcripts (Fig. S7). Thus, we studied the role of 
the p53 pathway by interfering with p53 itself and via inhibition of Chk proteins (Fig. 5a and 
5b). shRNA mediated knockdown of p53 in Sk-Mel-2 cells (Sk-Mel-2shRNA(p53)) reduced 
p53 protein levels (Fig. S8) and impaired Plk1i mediated reduction of cell viability (Fig. 5a).
As displayed in panels 5c and 5d, MM485 cells did not express detectable levels of p-p53 
protein. In line with the important role of p53 in Sk-Mel-2 cells, MM485 cells also showed 
low sensitivity to single Plk1i treatment (Fig. 2). p53 interference did not affect MEKi 
mediated reduction of cell viability. The efficacy of the MEK/Plk1 combination was also 
impaired by shRNA mediated p53-knockdown (Fig. 5a). This effect is, at least partly, a 
result of reduced Plk1i-mediated inhibition of cell viability.
Due to the critical role of p53 in the DNA damage response and its known activation by the 
checkpoint proteins Chk1 and Chk2, we investigated the effect of MEKi and Plk1i on cell 
viability in the presence of the Chk1/2 inhibitor PF-0477736 (Chk1/2i). Sk-Mel-2 cells 
treated with MEKi and Plk1i individually or in combination demonstrated a biphasic 
response to increasing Chk1/2i concentrations (Fig. 5b). This pattern could be the result of 
Chki being sufficient to mitigate checkpoint activation induced by Plk1i and, to a lesser 
extent, by MEKi in the low micromolar ranges, while higher concentrations result in 
increased genotoxicity and the complete abrogation of the DNA damage checkpoints. This 
hypothesis is supported by reports showing that Plk1 is involved in checkpoint adaptation 
with DNA damage checkpoint inhibition resulting in the sensitization of cancer cells to 
DNA damaging agents (Yoo et al. 2004; Jiang et al. 2009; Anderson et al. 2011). In support 
of a Chki specific effect, we were unable to recapitulate these results using other kinase 
inhibitors, such as CDK4i or receptor tyrosine kinase inhibitors added to the MEK/Plk1 
combination (data not shown).
The MEK/Plk1 inhibitor combination regresses human NRAS mutant melanoma xenografts
To test if the combination of a MEKi and a Plk1i is also effective in vivo, we established 
mouse melanoma xenografts using the human melanoma cell lines Sk-Mel-2 and WM3670. 
Single drugs or their combination were administered by oral gavage. The MEKi was given 
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at a dose of 2mg/kg/day leading to tumor size stabilization as demonstrated previously 
(Posch et al. 2013). The Plk1i was given 3 times per week to reach a total amount of 
50mg/kg/week and reduced tumor growth. Strikingly, combined MEK/Plk1 inhibition 
resulted in significant tumor shrinkage in all cell lines tested (Fig. 6a). No side effects of the 
combination therapy were observed. Immunoblot analyses of extracted tumor proteins 
revealed reduction of p/ERK, Plk1, p/AKT and p-RB. We further observed induction of the 
pro-apoptotic proteins BIM and BAX and a reduction of the anti-apoptotic protein Bcl-2 as 
well as increased caspase 3/7 activity in tumors treated with the combination of MEK/Plk1 
(Fig. 6b, S9).
Discussion
It is well established that specific mutations and defined signaling aberrations in cancer 
contribute to differences in the biological behavior of malignancies. Mutant RAS genes are 
found in up to one third of human cancer (Bos 1989; Repasky et al. 2004; Schubbert et al. 
2007) with NRAS mutations being the most prevalent in melanoma (Omerovic et al. 2007). 
Therapeutic modalities such as radiation therapy or chemotherapy for patients with NRAS 
mutant melanoma barely impact overall survival. Since direct inhibition of mutant NRAS is 
at present limited to preclinical models, pharmacologic interference with important RAS 
downstream signaling cascades seems to be the most promising treatment approach (Kwong 
et al. 2012; Posch et al. 2013; Vujic et al. 2014). One of the dominant signaling pathways in 
NRAS mutant melanoma is the MAPK pathway. Indeed, inhibition of the MAPK cascade 
with the MEK inhibitor MEK162 was tested in patients with NRAS mutant melanoma with 
encouraging results. However, responses were short and the development of resistance 
inevitable (Ascierto et al. 2013). This can, at least in part, be explained by the activation of 
other prosurvival pathways such as the PI3K/mTOR pathway after MEK inhibition (Fig. 3) 
(Posch et al. 2013). Thus, the search for effective co-extinction targets to MAPK inhibition 
is an ongoing and important area of research (Kwong et al. 2012; Ascierto et al. 2013; Posch 
et al. 2013).
Our data indicates that NRAS(Q61) mutations in PHM significantly increase Plk1 
expression. This observation might be linked to higher oncogenicity of NRAS(Q61) 
compared to NRAS(G12) mutations in melanocytic cells (Burd et al. 2014). Comparing Plk1 
levels of 6 NRAS(Q61) with 4 NRAS(G12) mutant melanoma cell lines also showed a trend 
towards higher Plk1 mRNA and protein expression in NRAS(Q61) cells; however, these 
analyses were not statistically significant (p=0.08; p=0.052; Fig. S10). Hence, we 
investigated if the a MEK/Plk1 inhibitor combination has antitumor activity in NRAS(G12) 
and NRAS(Q61) mutant melanoma cells.
Since the discovery of Plk proteins and proof of their biological importance in cancer 
maintenance, several compounds have been developed to target these molecules (Gumireddy 
et al. 2005; Lansing et al. 2007; Steegmaier et al. 2007; Beria et al. 2010). Among the 5 
mammalian Plk family members, selective Plk1 depletion appears to be most desirable. Plk1 
plays an important role throughout mitosis by influencing activation of CDK1/cyclin B, 
centrosome maturation, spindle formation, kinetochore assembly and regulation of 
microtubule nucleation as well as chromosome segregation and execution of cytokinesis 
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(Lane and Nigg 1996; Seong et al. 2002; Sumara et al. 2004; van Vugt et al. 2004; Cholewa 
et al. 2014). Results presented in this study suggest that NRAS mutations are linked to high 
Plk1 expression. This is supported by findings in a model of transduced PHM as well as in a 
representative collection of melanoma lines. Additionally, when evaluating clinical data 
from The Cancer Genome Atlas (TCGA) of cutaneous melanoma, mutations in NRAS and 
increased expression of Plk1 co-occur (p=0.009) (Cerami et al. 2012; Gao et al. 2013). Even 
though further research is needed to address potential connections of RAS signaling and 
Plk1 expression, our results support current knowledge, highlighting the importance of Plk1 
for viability of RAS activated malignancies (Luo et al. 2009; Wang et al. 2013; Yim and 
Erikson 2014). Still, cancer therapy with Plk1 inhibitors alone is ineffective clinically (Luo 
et al. 2009). It is believed that the somewhat low response rates might be explained by 
undesired co-targeting of Plk2 and Plk3, which attenuates the growth inhibitory effects of 
Plk1 abrogation (Strebhardt 2010).
In combination with MEK inhibition, however, we observe significant cell death in vitro and 
tumor shrinkage as well as induction of apoptosis in vivo (Fig. 6). The importance of cell 
cycle regulation in NRAS mutant melanoma has previously been shown. Recent findings 
using MEK/CDK4,6 inhibitor combinations support this notion, with promising (pre)clinical 
results (Kwong et al. 2012). However, several NRAS mutant cells and clinical tumors do not 
respond to treatment with MEK/CDK4,6 inhibitors. This might be explained by recent 
findings suggesting that NRAS mutation status may only determine response to this 
combination, when evaluated in tandem with aberrations in CDKN2A (Dong 2013). Data 
presented in the present study reveal, however, that the MEK/Plk1 inhibitor combination 
reduces cell growth independent of CDKN2A and Plk1 mutations (Fig. 2, S1, table S1).
Mounting evidence suggests that Plk1 affects p53 via direct binding and subsequent 
inhibition of its pro-apoptotic function (Ando et al. 2004). Accordingly, our findings show 
that the efficacy of Plk1 inhibition is related to p53 expression, because i) functional shRNA 
mediated knockdown of p53 in Sk-Mel-2 cells reduced the inhibitory effects of Plk1 and 
MEK/Plk1 treatment, and ii) cells with high p-p53(Ser15) protein expression showed a trend 
towards requiring less Plk1 inhibitor to reach GI50 (Fig. S11) compared to cells with low or 
non-detectable p-p53(Ser15) protein expression (Tsvetkov et al. 2003; Ando et al. 2004; 
Strebhardt 2010).
In addition to RNA silencing of p53, pharmacologic Chk1/2 inhibition also influenced the 
efficacy of combined MEK/Plk1 inhibition. However, it should be mentioned that even in 
cells with low p53 protein expression, MEK/Plk1 treatment effectively reduced cell growth, 
suggestive of other factors contributing to the inhibitory activity of this combination. While 
studies investigating the role of Plk1 in p53 signaling and its function outside of mitosis are 
scarce (Cholewa et al. 2013), possible redundancy with p53 family members, p63 and p73, 
need to be considered. In HeLa cells p73 is capable of inducing p21 expression in p53-
inactivated cells following Plk1 inhibition, which results in greater sensitivity to additional 
therapeutics (Kreis et al. 2009). Furthermore, it has been reported that Plk1 phosphorylates 
and thus suppresses p63 mediated cell death in liver tumor cells (Komatsu et al. 2009). 
Taken together, our data offers important insights into the Plk1-p53 axis, which warrants 
further investigation.
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In addition to the induction of pro-apoptotic signals in vitro and in vivo, MEK/Plk1 also 
caused dual cell cycle arrest. The MEKi-induced G1 arrest can potentially be attributed to 
the reduction in cyclin D expression. Cyclin D is required for cell cycle reentry and has 
previously been shown to be abrogated in response to MEK inhibition (Modi et al. 2012; 
Atefi et al. 2015). Plk1i induces a G2/M arrest through aberrant spindle pole formation, 
which ultimately results in mitotic catastrophe and subsequent apoptosis (Schmit et al. 
2009). Results of this study suggest that cells escaping G1 arrest induced by MEK 
inhibition, or cells escaping G2/M arrest resulting from Plk1 inhibition, maintain their 
susceptibility to the other drug in combination.
In this study, we provide first in vitro and in vivo results, that a MEK/Plk1 combination 
might be a promising approach for the treatment of NRAS driven melanoma. Of note, and in 
support of signaling similarities across several NRAS mutant malignancies (Vujic et al. 
2014), this inhibitor combination also reduced viability in one NRAS mutant neuroblastoma 
and one NRAS mutant lung cancer cell line in vitro (Fig. S12). This is particularly 
important, as effective therapeutic modalities for patients with NRAS mutant tumors of 
various etiologies are limited.
Material and Methods
Cell culturing, growth inhibition experiments and immunoblotting were preformed as 
previously described (Posch et al. 2013). Detailed material and methods as well as 
information on lentiviral production, transduction, cell cycle analyses, the custom mRNA 
array and qPCR including primer sequences (table S4) can be found in the electronic 
supporting information. Delta CT and deltadelta CT values of the custom mRNA array are 
provided in table S5. Xenograft studies were performed in CrTac:NCr-Foxn1nu mice. 
Inhibitor treatment was administered by oral gavage when tumors reached a volume of 
80/100mm^3. All animal studies were approved by IACUC/LARC of the University of 
California San Francisco (AN086990).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. NRAS mutant cell lines express high levels of Plk1 mRNA
(a) Relative expression of Plk1 in 23 human melanoma cell lines. NRAS mutant melanoma 
cell lines show higher Plk1 expression compared to non-NRAS and, in particular, to 
BRAF(V600) mutant cell lines. (b) Plk1 expression in stably transduced primary human 
melanocytes (PHM) expressing the indicated NRAS mutations or an empty vector control 
(E). NRAS(Q61) mutant cells show a significant increase of Plk1 expression on mRNA and 
protein level compared to empty vector controls, non-oncogenic NRAS(N24) mutants and 
NRAS(G12) mutant cells. Bars represent the mean relative expression of Plk1. β-actin 
served as an endogenous control. (N=3; * indicates p<0.05; mean±SEM)
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Figure 2. Dose dependent reduction of cell viability with inhibitors of MEK and Plk1
Dose response curves of 5 NRAS mutant melanoma cell lines (WM3629, WM3670, Sk-
Mel-2, MM485 and D04) using inhibitors of MEK, Plk1 or their combination. All cell lines 
were sensitive to MEK and Plk1 inhibition as well as the combination of both inhibitors. 
(GI50 = concentration at 50% growth inhibition; N=3; mean±SD; one unit of inhibitor 
represents 1nM of the MEK inhibitor JTP/74057 and 8nM for the Plk1 inhibitor BI6727)
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Figure 3. Regulation of cell cycle genes, and p53/p21 signaling members with inhibitors of MEK 
and Plk1
(a) Hierarchical clustering of mRNA levels in 2 NRAS mutant lines in response to the 
respective inhibitors after 6h and 24h of incubation. The expression patterns were similar in 
both cell lines. Several cell cycle related genes were affected by the single inhibitors and the 
MEK/Plk1 combination. (b) Immunoblot analyses of the human melanoma lines Sk-Mel-2 
and D04 and corresponding bar graphs for relative protein expression. Reduced phospho-
protein levels of ERK and S6 in MEK inhibitor treated conditions. Induction of p-AKT in 
Sk-Mel-2 cells after MEK inhibition. Reduction of p-AKT, p-ERKT and p-S6 as well as 
induction of CCNB1 by the combination treatment. (*greater than 200%; mean±SD; N=3)
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Figure 4. Induction of apoptosis and cell cycle arrest with the MEK/Plk1 combination
(a) Earlier and pronounced decrease of cell viability over time and (b) earlier and stronger 
induction of caspase 3/7 activity with the MEK/Plk1 combination. (c) G0/G1 arrest in MEKi 
treated groups and G2/M arrest in BI6727 treated cells. The combination of both inhibitors 
caused a dose dependent dual G1 (red) and G2/M (blue) arrest. (d) Double thymidine block 
and time course analyses of cell cycle progression showed a G1 arrest with the MEKi. 
Progressing cells in the combinational treatment group succumb to G2/M arrest induced by 
the Plk1i. (e) The thymidine-nocodazole block revealed continuous G2/M arrest after Plk1i 
treatment. (N=3; mean±SD; MEKi(JTP/74017)=20nM; Plk1i(BI6727)=100nM)
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Figure 5. p-53 signaling affects Plk1 and MEK/Plk1 inhibitor efficacy
a. Stable knockdown of p53 reduced the activity of Plk1 and MEK/Plk1 inhibition. p53 
interference had no effect on viability in cells treated with the MEKi only, or on vehicle 
treated cells. (b) Additional Inhibition of Chk1/2 markedly reduced viability in MEK/Plk1 
treated compared to single inhibitor or vehicle treated controls in a biphasic manner. (c) 
Immunoblot analyses of p-p53 and Plk1 in all 10 NRAS mutant cell lines used in this study. 
All cells, except MM485, express p-p53. Plk1 protein expression was pronounced in 
NRAS(Q61) mutant cells. (d) Relative expression of the respective proteins compared to β/
actin. (N=3; mean±SD; SCR=scramble control shRNA; MEKi(JTP-74057)=20nM; 
Plk1i(BI6727)=100nM; Chk1/2i=PF-0477736)
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Figure 6. Tumor size reduction of NRAS mutant xenografts with the MEK/Plk1 combination
(a) Treatment of established mouse xenografts showed tumor size reduction after initiation 
of treatment (day 0) with the combination of a MEKi (2 mg*kg−1*d−1) and Plk1i (50 
mg*kg−1*week−1), but not with either MEKi or Plk1i alone. (cell lines: Sk-Mel-2, 
WM3670; MEKi: JTP-74057; Plk1i: BI6727; n=4) Results are displayed as the mean change 
in tumor volume at indicated time points ± SD. (b) Corresponding immunoblot analyses of 
mouse tumors after 3 weeks of treatment with the indicated conditions.
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